-
2026-03-09
双靶点新药落地大湾区！
-
2026-01-27
优锐医药宣布中国国家药品监督管理局正式受理恩司芬群（Ensifentrine，Ohtuvayre®
-
2026-01-23
优锐医药宣布倍悠朗鼻喷剂在中国获批上市
-
2025-09-08
优锐医药宣布与Stallergenes Greer就Actair®达成独家长期合作
-
2025-06-16
优锐医药宣布恩司芬群Ensifentrine在COPD三期临床试验ENHANCE-CHINA中达到主要终点
-
2025-02-07
优锐医药宣布恩司芬群（Ensifentrine，Ohtuvayre™）在中国澳门特别行政区获批
-
2024-09-23
优锐医药与Altamira Therapeutics签署独家协议，在部分东亚与东南亚市场开发和经销百畅悠（Bentrio）鼻喷剂
优锐医药今日宣布与Altamira Medica Ltd.签署独家协议，授权优锐在部分东亚及东南亚市场开发和商业化百畅悠（Bentrio）鼻喷剂。
-
2024-09-23
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
Altamira Medica Ltd. has agreed with its partner Nuance Pharma to extend the territory covered by their exclusive license and distribution agreement for Bentrio® nasal spray by several countries across South East and East Asia.
Contact PR
